argentin
haemorrhag
fever
ahf
rodentborn
diseas
lethal
high
caus
new
world
arenaviru
viru
junv
major
epidem
south
america
put
million
peopl
argentina
risk
aim
develop
hors
antibodi
antibodi
fragment
junv
prepar
hors
antibodi
strategi
effici
gener
hors
antisera
establish
base
comparison
among
immunogen
immun
method
mice
hors
antisera
junv
final
obtain
vaccin
hors
vesicular
stomat
viru
pseudotyp
bear
junv
gp
hors
antibodi
igg
f
ab
subsequ
demonstr
effect
neutral
vesicular
stomat
viru
pseudotyp
bear
junv
gp
show
crossneutr
pathogen
new
world
arenavirus
research
reveal
import
site
bind
antibodi
target
mainli
junv
neutral
collect
studi
present
effici
strategi
develop
hors
antisera
junv
provid
hors
antibodi
potenti
therapeut
ahf
envelop
rna
virus
caus
human
viral
haemorrhag
fever
includ
mainli
filo
flavi
bunya
arenavirus
paessler
walker
virus
preval
worldwid
infect
peopl
area
poor
public
health
gonzalez
et
al
new
world
nw
arenavirus
viru
junv
machupo
viru
macv
guanarito
viru
gtov
sabia
viru
sbav
chapar
viru
chapv
uninterruptedli
break
south
american
countri
argentina
bolivia
venezuela
brazil
gonzalez
et
al
mclay
et
al
pontremoli
et
al
asymptomat
resid
rodent
highli
pathogen
human
occasion
infect
skin
respiratori
tract
gastrointestin
mucosa
radoshitzki
et
al
due
high
fatal
rate
high
limit
prophylact
therapeut
identifi
biosafeti
level
bsl
pathogen
countri
except
junv
handl
bsl
lab
certain
circumst
nunberg
york
junv
one
import
nw
arenavirus
aetiolog
agent
argentin
haemorrhag
fever
ahf
almost
five
million
peopl
argentina
risk
enria
et
al
know
attenu
liveviru
vaccin
candid
licens
argentina
markedli
reduc
mortal
rate
ahf
maiztegui
et
al
human
immunoglobulin
g
igg
convalesc
individu
current
main
therapeut
option
ahf
risk
viral
transmiss
human
concern
regard
shortag
plasma
may
exist
enria
et
al
kenyon
et
al
ruggiero
et
al
henc
addit
drug
urgent
need
sever
monoclon
antibodi
mab
junv
report
recent
year
includ
humanmous
chimaera
mab
modifi
zeitlin
et
al
vaccineelicit
human
mab
discov
clark
et
al
seri
mous
mab
identifi
group
pan
et
al
mab
target
envelop
glycoprotein
complex
gpc
neutral
consist
trimer
noncoval
bound
subunit
receptor
recognit
subunit
glycoprotein
membranefus
subunit
glycoprotein
stabl
signal
peptid
ssp
radoshitzki
et
al
wang
et
al
although
one
singledomain
antibodi
target
nucleoprotein
also
report
neutral
candid
vitro
linero
et
al
report
neutral
antibodi
nab
junv
demonstr
target
addit
mab
polyclon
antibodi
also
play
role
combat
junv
infect
immun
rabbit
demonstr
protect
guinea
pig
lethal
junv
challeng
golden
et
al
fact
hors
antiserumderiv
polyclon
antibodi
demonstr
good
efficaci
infecti
diseas
caus
highli
pathogen
agent
ebola
viru
wang
et
al
zheng
et
al
west
nile
viru
cui
et
al
influenza
viru
lu
et
al
sever
acut
respiratori
syndrom
viru
lu
et
al
middl
east
respiratori
syndrom
coronaviru
zhao
et
al
extens
report
thu
studi
polyclon
antibodi
junv
prepar
hors
antisera
antibodi
achiev
goal
differ
immunogen
immun
strategi
first
test
mice
hors
antisera
prepar
hors
vaccin
vesicular
stomat
viru
vsv
pseudotyp
bear
junv
gp
subsequ
demonstr
contain
abund
nab
junv
total
igg
purifi
f
ab
obtain
remov
fc
igg
pepsin
digest
specif
igg
f
ab
prepar
affin
chromatographi
recombin
junv
final
neutral
activ
verifi
vsv
pseudotyp
bear
junv
gp
recombin
vsv
express
junv
gp
along
four
pathogen
nw
arenavirus
antibodi
specif
final
found
bind
import
site
studi
present
effici
strategi
prepar
hors
nab
junv
provid
foundat
develop
potenti
therapeut
ahf
hela
cell
maintain
dulbecco
modifi
eagl
medium
dmem
gibco
grand
island
ny
supplement
foetal
bovin
serum
fb
gibco
co
cell
cultur
freestyl
express
medium
invitrogen
carlsbad
ca
incub
co
shake
rpmmin
vsv
pseudoviru
packag
perform
describ
first
gpc
gene
junv
genbank
macv
genbank
gtov
genbank
sbav
genbank
chapv
genbank
synthes
genscript
co
ltd
nanj
china
separ
insert
restrict
site
eukaryot
express
vector
pcagg
gener
pcaggsjunv
gpc
pcaggsmacv
gpc
pcaggsgtov
gpc
pcaggssbav
gpc
pcaggschapv
gpc
respect
cell
seed
dish
transfect
pcaggsjunv
gpc
plasmid
h
infect
g
g
whitt
packag
laboratori
member
h
subsequ
cell
supernat
complet
remov
cultur
supernat
contain
pseudoviru
gpc
gpc
collect
h
vsv
pseudotyp
bear
macv
gtov
sbav
chapv
gp
packag
way
vsv
pseudotyp
bear
junv
gp
pseudovirus
restrict
singl
round
replic
thu
enabl
handl
bsl
lab
packag
recombin
vsv
express
junv
gp
perform
describ
previous
garbutt
et
al
wang
et
al
briefli
junv
gpc
gene
clone
plasmid
addgen
site
gener
gpc
cell
seed
plate
overnight
cultur
supernat
remov
cell
infect
recombin
vaccinia
viru
encod
rna
polymeras
moi
fortyf
minut
later
infecti
mixtur
complet
remov
cell
wash
dmem
total
plasmid
pbsn
pbsp
pbsg
pbsl
gpc
ratio
transfect
cell
use
lipofectamin
invitrogen
h
supernat
collect
flow
filter
remov
residu
vaccinia
viru
inocul
cell
transfect
pcaggsvsv
g
h
previous
four
day
later
supernat
collect
passag
cell
obtain
thirdgener
viru
gpc
exclus
express
junv
gp
viral
titr
measur
cell
calcul
fluoresc
plaqu
codonoptim
junv
gpc
synthes
genscript
co
ltd
plasmid
pcaggsjunv
gpc
gener
usual
purifi
e
coli
endotoxinfre
plasmid
extract
kit
invitrogen
carlsbad
ca
gpc
collect
cultur
supernat
subject
ultracentrifug
sucros
solut
obtain
pure
viral
particl
sequenc
aa
amplifi
junv
gpc
gener
plasmid
transfect
cell
polyethylenimin
pei
polysci
warrington
pa
sodium
valproat
mm
ad
control
overgrowth
cell
cell
cultur
supernat
collect
day
later
dialys
phosphat
buffer
nacl
mm
nah
po
ph
subject
nisepharos
purif
recombin
elut
mm
imidazol
dialys
use
anim
experi
perform
strictli
accord
regul
administr
affair
concern
experiment
anim
china
protocol
approv
laboratori
anim
care
use
committe
wuhan
institut
virolog
chines
academi
scienc
wuhan
china
femal
balbc
mice
age
week
hous
specif
pathogenfre
anim
care
facil
mice
divid
four
group
n
group
homogen
primeboostboost
protocol
appli
group
mice
receiv
recombin
pcaggsjunv
gpc
gpc
vaccin
via
differ
rout
phosphatebuff
salin
pb
use
control
vaccin
perform
three
time
total
twoweek
interv
detail
recombin
pseudovir
particl
mix
freund
complet
adjuv
sigmaaldrich
st
loui
mo
prime
mix
freund
incomplet
adjuv
sigmaaldrich
boost
protein
per
mous
pseudovir
particl
focusform
unit
ffu
mix
adjuv
volum
use
intraderm
subcutan
intraperiton
lymphat
inject
mous
pcaggsjunv
gpc
plasmid
dilut
pb
mgml
volum
equal
inject
two
leg
mous
mice
subject
electropor
electroporat
btx
san
diego
ca
set
paramet
v
ms
six
healthi
hors
age
year
old
divid
three
group
hors
homogen
receiv
subcutan
intramuscular
multipoint
inject
dna
mg
aluminium
phosphat
pseudovir
particl
ffu
aluminium
hydroxid
immun
implement
week
serum
sampl
collect
jugular
vein
week
monitor
variat
antibodi
respons
immun
hors
plasma
collect
plasma
collect
machin
preserv
analysi
purif
total
igg
plasma
first
dilut
pb
mm
nacl
mm
nah
po
ph
ratio
filter
filter
subject
affin
chromatographi
protein
aconjug
resin
prepar
total
f
ab
pepsin
sigmaaldrich
use
remov
fc
igg
detail
total
igg
first
dilut
sodium
acet
buffer
ph
mg
ml
pepsin
ad
mass
proport
digest
reaction
perform
h
termin
ad
trisbas
buffer
ph
adjust
ph
digest
product
subject
protein
column
remov
residu
igg
fc
fragment
follow
concentr
kda
ultrafiltr
devic
remov
small
protein
purif
igg
recombin
express
cell
describ
coupl
preactiv
resin
pabpursulfolink
bead
smart
life
scienc
changzhou
amino
reaction
resin
use
purifi
igg
total
igg
elut
compon
igg
flowthrough
compon
residu
igg
affin
chromatographi
collect
respect
f
ab
acquir
purifi
f
ab
total
f
ab
manner
igg
antibodi
maintain
pb
use
verifi
puriti
size
igg
f
ab
prepar
studi
nonreduc
reduc
sdspage
employ
nonreduc
sampl
prepar
mix
protein
load
buffer
mm
trishcl
glycerol
sd
bromophenol
blue
ad
neither
ddt
reduc
sampl
prepar
mix
protein
load
buffer
ad
boil
water
min
nonreduc
reduc
sampl
concentr
sdspage
separ
sdspage
final
sdspage
gel
stain
coomassi
brilliant
blue
imag
gel
decolour
captur
chemidoc
mp
imag
system
biorad
peptid
elisa
recombin
peptid
dilut
coat
buffer
nahco
ph
pseudoviruscaptur
elisa
pseudovir
particl
dilut
coat
buffer
ffuml
antigen
diluent
ad
polystyren
plate
plate
incub
c
overnight
complet
antigen
coat
cellbas
elisa
pcaggsjunv
gpc
transfect
hela
cell
ng
well
plate
cultur
supernat
discard
h
later
cell
fix
paraformaldehyd
coat
plate
wash
three
time
pbstween
block
fb
room
temperatur
h
subsequ
liquid
plate
aspir
well
wash
time
sampl
dilut
sera
antibodi
volum
ad
well
pb
irrelev
antibodi
use
control
plate
place
room
temperatur
h
implement
bind
step
liquid
plate
aspir
well
wash
incub
secondari
antibodi
conjug
horseradish
peroxidas
hrp
catalogu
number
proteintech
china
room
temperatur
anoth
hour
wash
ad
plate
place
dark
approxim
min
chromogen
reaction
termin
ad
h
final
absorb
nm
measur
micropl
reader
tecan
swiss
valu
greater
twice
control
consid
posit
cell
seed
plate
overnight
pseudoviru
gpc
junpv
gpc
macpv
gpc
gtopv
gpc
sbapv
gpc
chappv
gpc
dilut
titr
recombin
vsv
express
junv
gpc
gpc
incub
gradientdilut
sera
antibodi
h
mixtur
ad
cell
implement
infect
h
supernat
complet
remov
cell
cultur
h
final
cell
subject
luminesc
detect
use
luciferas
assay
kit
catalogu
number
promega
wi
usa
accord
manufactur
instruct
imag
gfpexpress
cell
captur
fluoresc
microscop
olympu
japan
number
fluoresc
dot
foci
infect
count
imagej
nation
institut
health
affin
igg
f
ab
monitor
biolay
interferometri
bli
use
octetr
devic
pall
fortebio
llc
ca
accord
previous
describ
protocol
pan
et
al
briefli
recombin
biotinyl
room
temperatur
h
incub
biotin
molar
ratio
residu
biotin
remov
dialysi
pb
biotinyl
load
onto
streptavidin
biosensor
fortebio
satur
igg
f
ab
dilut
differ
concentr
load
kinet
associ
k
dissoci
k
measur
data
process
octet
data
analysi
system
sixteen
peptid
overlap
synthes
genscript
co
ltd
accord
sequenc
aa
amino
acid
sequenc
list
supplementari
materi
mutat
aa
tyr
ala
aa
asp
ala
aa
tyr
ala
aa
asp
ala
also
synthes
recombin
mutat
aa
tyr
ala
aa
asp
ala
aa
tyr
ala
aa
asp
ala
express
purifi
describ
wildtyp
one
correspond
mutat
gener
pcr
sitedirect
mutagenesi
elisa
mutat
peptid
perform
describ
section
data
analys
use
graphpad
prism
softwar
san
diego
ca
usa
present
mean
sd
base
least
three
independ
experi
except
specif
note
figur
legend
statist
analysi
perform
use
oneway
anova
dunnett
test
p
valu
defin
p
p
suitabl
immunogen
key
stimul
nab
vivo
gpc
mediat
entri
junv
respons
receptor
recognit
systemat
analys
effect
gpc
stimul
nab
mice
employ
recombin
express
cell
fulllength
gpc
gene
vector
eukaryot
express
plasmid
intact
gpc
display
vsv
pseudoviru
fig
comparison
immunogen
mice
sera
mous
collect
one
week
third
vaccin
titr
specif
antibodi
sera
recombin
group
pcaggsjunv
gpc
group
pseudoviru
group
correspondingli
detect
recombin
cellbas
pseudoviruscaptur
elisa
respect
b
c
sera
recombin
group
pcaggsjunv
gpc
group
pseudoviru
group
collect
one
week
vaccin
sera
group
pool
pvnt
character
gpc
cell
dilut
ratio
sera
rang
titr
neutral
nt
nt
mark
fig
comparison
immun
strategi
hors
six
hors
divid
three
group
two
hors
group
hors
homogen
vaccin
vsv
pseudovir
particl
bear
junv
gp
hors
vaccin
dna
first
two
time
vsv
pseudotyp
bear
junv
gp
last
two
time
hors
homogen
vaccin
dna
correspond
amount
pseudoviru
dna
list
b
hors
vaccin
four
time
total
twoweek
interv
three
group
follow
immun
schedul
serum
sampl
collect
one
week
vaccin
c
titr
specif
antibodi
sera
detect
cellbas
pseudoviruscaptur
elisa
e
pvnt
sera
hors
immun
character
gpc
data
group
two
hors
x
pan
et
al
antivir
research
immunogen
mice
group
subject
continu
homogen
vaccin
describ
method
section
sera
collect
differ
time
point
monitor
antibodi
respons
fig
sera
recombin
pcaggsjunv
gpc
pseudoviru
group
collect
last
vaccin
detect
proteincaptur
cellbas
pseudoviruscaptur
elisa
respect
titr
antigenspecif
antibodi
three
group
high
indic
three
kind
immunogen
employ
studi
abl
stimul
strong
antibodi
respons
mice
variat
nab
monitor
pseudoviru
neutral
test
pvnt
vaccin
shown
fig
neutral
titr
pvnt
sera
group
approxim
three
vaccin
howev
pvnt
sera
dna
pseudoviru
group
high
fig
pvnt
obvious
elev
first
boost
obvious
elev
second
boost
although
protein
dnajunv
gpc
pseudoviru
exhibit
similar
abil
trigger
antigenspecif
antibodi
product
mice
dnajunv
gpc
vsv
pseudotyp
bear
junv
gp
trigger
nab
better
protein
thu
immunogen
dnajunv
gpc
pseudoviru
employ
vaccin
hors
six
hors
three
group
either
homogen
receiv
pseudoviru
dna
heterogen
receiv
dna
pseudoviru
fig
three
group
maintain
schedul
vaccin
four
time
total
twoweek
interv
fig
sera
six
hors
vaccin
collect
monitor
antigenspecif
antibodi
either
cellbas
elisa
pseudoviruscaptur
elisa
shown
fig
titr
specif
antibodi
sera
hors
group
markedli
increas
number
vaccin
titr
sera
hors
group
bare
chang
compar
titr
determin
cellbas
elisa
shown
fig
titr
specif
antibodi
detect
pseudoviruscaptur
elisa
shown
fig
differ
titr
specif
antibodi
sera
group
remark
elev
boost
hors
remain
unchang
result
demonstr
either
homogen
vaccin
pseudoviru
dna
could
effect
stimul
antigenspecif
antibodi
hors
combin
vaccin
dna
pseudoviru
could
achiev
desir
goal
addit
antibodi
trigger
pseudoviru
could
recogn
gpc
display
viru
also
gpc
express
cell
surfac
variat
nab
six
hors
monitor
pvnt
immun
shown
fig
pvnt
sera
hors
group
substanti
increas
number
vaccin
four
hors
bare
chang
base
result
conclud
homogen
vaccin
pseudoviru
could
success
gener
nab
high
titr
hors
superior
two
immun
strategi
sera
hors
taken
analysi
neutral
activ
character
vsv
pseudotyp
bear
junv
gp
shown
fig
sera
hors
neutral
vsv
pseudotyp
bear
junv
gp
dosedepend
manner
pvnt
pvnt
high
respect
inhibit
vsv
pseudotyp
bear
junv
gp
carri
gfp
report
gene
shown
fig
number
gfpexpress
cell
shown
imag
significantli
reduc
treatment
gradientdilut
sera
specif
approxim
vsv
pseudotyp
bear
junv
gp
inhibit
sera
dilut
vsv
pseudotyp
bear
junv
gp
inhibit
sera
dilut
result
shown
fig
consist
shown
fig
subsequ
explor
crossneutr
five
pathogen
nw
arenavirus
junv
macv
gtov
sbav
chapv
hors
sera
shown
fig
mix
sera
hors
show
moder
neutral
macpv
gtopv
sbapv
chappv
pvnt
four
pathogen
nw
arenavirus
rang
pvnt
around
except
neutral
macpv
nt
reach
use
dilut
result
illustr
hors
antisera
prepar
via
establish
strategi
possess
crossneutr
capabl
five
pathogen
nw
arenavirus
extent
strongest
neutral
junv
bulk
antisera
collect
hors
purif
antibodi
total
igg
f
ab
along
fig
neutral
sera
pseudovirusvaccin
hors
sera
hors
collect
immun
neutral
junv
character
gpc
dilut
ratio
sera
rang
b
neutral
sera
character
gpc
dilut
ratio
sera
indic
figur
imag
captur
h
infect
data
repres
experi
c
neutral
mix
sera
hors
five
pathogen
nw
arenavirus
character
vsv
pseudotyp
bear
junv
macv
gtov
sbav
chapv
gp
respect
dilut
ratio
group
rang
nt
nt
mark
x
pan
et
al
antivir
research
specif
igg
f
ab
prepar
describ
detail
method
section
igg
f
ab
yield
one
fiftieth
total
igg
total
f
ab
respect
affin
chromatographi
eukaryot
igg
f
ab
detect
nonreduc
reduc
sdspage
actual
size
consist
theoret
size
shown
fig
set
pvnt
inhibitori
concentr
ic
ic
antibodi
obtain
present
fig
ic
valu
total
igg
total
f
ab
respect
igg
f
ab
lower
ic
total
igg
total
f
ab
respect
addit
ic
total
igg
total
f
ab
igg
f
ab
respect
furthermor
residu
igg
collect
flowthrough
fraction
chromatographi
hardli
neutral
vsv
pseudotyp
bear
junv
gp
even
concentr
result
collect
demonstr
purif
could
significantli
enrich
nab
total
igg
f
ab
turn
confirm
import
target
nab
sera
prepar
studi
verifi
neutral
abil
antibodi
recombin
vsv
express
junv
gp
gpc
perman
carri
egfp
report
recombin
replac
vsv
g
junv
gpc
could
form
fluoresc
plaqu
cell
thu
avoid
handl
live
junv
bsl
laboratori
shown
fig
either
igg
f
ab
total
igg
total
f
ab
obvious
reduc
gfpposit
plaqu
cell
ic
reduct
gfpposit
plaqu
signific
antibodi
given
ic
result
fig
test
recombin
viru
similar
test
pseudoviru
shown
fig
furthermor
explor
crossneutr
igg
five
nw
arenavirus
hors
antisera
demonstr
crossneutr
abil
five
nw
arenavirus
shown
fig
set
pvnt
ic
ic
four
pseudovirus
obtain
list
fig
consequ
igg
neutral
macpv
gtopv
sbapv
chappv
ic
ic
respect
contrast
neglig
neutral
observ
vsv
pseudoviru
collect
deem
antibodi
purifi
hors
sera
igg
possess
strong
neutral
abil
junv
neutral
four
pathogen
nw
arenavirus
extent
fig
neutral
junv
hors
igg
f
ab
purifi
igg
f
ab
detect
nonreduc
reduc
sdspage
size
intact
igg
f
ab
approxim
kda
kda
respect
size
heavi
chain
light
chain
approxim
kda
kda
respect
b
neutral
total
igg
total
f
ab
igg
f
ab
character
gpc
residu
igg
use
control
correspond
ic
ic
calcul
list
c
neutral
four
antibodi
character
gpc
inhibit
plaqu
format
captur
fluoresc
microscop
two
day
infect
cell
gpc
moi
work
concentr
ic
imag
repres
experi
crossneutr
junv
igg
pathogen
nw
arenavirus
junv
macv
gtov
sbav
chapv
character
pseudovirus
vsv
pseudotyp
bear
vsv
g
use
control
ic
ic
list
sinc
purif
significantli
enrich
neutral
activ
igg
f
ab
tri
analys
bind
use
set
bia
kinet
bind
dissoci
recombin
determin
shown
fig
b
k
total
igg
f
ab
nm
nm
respect
k
igg
f
ab
nm
nm
respect
fig
reflect
affin
chromatographi
success
select
highaffin
binder
total
fraction
locat
preferenti
bind
site
bind
igg
sixteen
peptid
deriv
detect
elisa
fig
fifth
peptid
aa
strongli
bound
antibodi
among
sixteen
peptid
use
posit
control
comparison
residu
igg
weakli
bound
peptid
reflect
littl
nonspecif
bind
fact
overlap
neutral
epitop
report
mahmutov
et
al
report
zeltina
et
al
fig
verifi
import
neutral
antibodi
prepar
studi
employ
mutat
peptid
antigen
anoth
two
set
elisa
result
mutat
site
partial
abolish
bind
antibodi
similar
degre
fig
valid
result
recombin
mutat
mutat
impair
bind
mutat
fig
thu
specul
import
site
bind
nab
highli
pathogen
arenavirus
five
clade
b
nw
arenavirus
junv
macv
gtov
sbav
chapv
share
analog
envelop
glycoprotein
structur
employ
receptor
transferrin
receptor
entri
human
cell
caus
similar
symptom
human
howev
report
nab
rare
possess
crossneutr
mab
target
sequenceconserv
consid
promis
antibodi
crossreact
nw
old
world
arenavirus
neutral
neither
amanat
et
al
nab
junv
simpli
target
report
crossneutr
capabl
five
arenavirus
except
one
elicit
candid
neutral
junv
macv
vari
effici
vitro
clark
et
al
contrast
mab
polyclon
antibodi
report
neutral
junv
macv
gtov
sbav
achiev
vaccin
rabbit
mix
plasmid
encod
gpc
four
nw
arenavirus
golden
et
al
studi
antisera
junv
igg
purifi
antisera
crossneutr
effect
five
nw
clade
b
arenavirus
although
result
valid
vsv
pseudotyp
bear
arenavir
gp
may
differ
valid
actual
virus
beyond
exact
crossneutr
mechan
clear
one
clue
antisera
produc
vaccin
hors
pseudoviru
fig
affin
igg
f
ab
junv
data
collect
bli
kinet
k
k
process
octet
data
analysi
system
bind
curv
obtain
pass
total
igg
total
f
ab
igg
f
ab
differ
concentr
biotinyl
recombin
immobil
streptavidin
biosensor
surfac
kinet
valu
k
calcul
deduct
baselin
fit
associ
dissoci
respons
langmuir
bind
model
data
one
strict
experi
express
gpc
react
pseudovirusexpress
gpc
also
cellexpress
gpc
result
impli
antisera
junv
igg
purifi
antisera
might
target
diversiform
flexibl
structur
gpc
work
thu
escap
hinder
tini
structur
differ
among
five
virus
anoth
clue
may
bound
key
site
conserv
across
five
nw
arenavirus
even
studi
crossnab
pathogen
nw
arenavirus
earli
stage
requir
valid
explor
addit
crossneutr
five
nw
pathogen
arenavirus
remain
major
challeng
attent
paid
structur
similar
rather
sequenc
similar
current
commerci
process
obtain
hors
antiserum
deriv
matur
countri
remov
fc
igg
enabl
hors
f
ab
accept
immun
therapeut
reduc
side
effect
complex
intract
diseas
especi
snakebit
highli
pathogen
infecti
diseas
guidolin
et
al
ratanabanangkoon
et
al
wang
et
al
even
disadvantag
limit
wide
applic
hors
f
ab
fragment
fulllength
igg
hors
f
ab
function
antibodydepend
cellular
cytotox
complementdepend
cytotox
crystallis
receptormedi
crosspresent
contribut
fc
consid
import
protect
vivo
chung
et
al
mehlhop
et
al
yu
et
al
heterolog
protein
human
immun
system
hors
f
ab
may
suscept
immun
resist
thu
larg
therapeut
dose
administ
appli
clinic
howev
hors
antibodi
advantag
multitarget
mode
action
differ
mab
moreov
multitarget
action
affect
multipl
epitop
pathogen
also
multipl
epitop
differ
pathogen
thu
provid
irreplac
advantag
broadspectrum
antivir
drug
despit
hors
f
ab
develop
studi
potenti
therapeut
studi
provid
anoth
possibl
ahf
therapi
studi
base
substanti
explor
immunogen
immun
strategi
final
prove
pseudovir
particl
decor
matur
gpc
abl
stimul
abund
nab
mice
hors
find
provid
good
immunogen
prepar
hors
antiserum
junv
addit
eukaryot
express
vector
insert
fulllength
gpc
gene
vaccin
electropor
realiz
express
situ
exhibit
capac
stimul
nab
similar
pseudovir
particl
mice
dna
immun
confirm
good
way
stimul
antibodi
mice
guinea
pig
group
pan
et
al
golden
et
al
golden
et
al
howev
dna
immun
hors
exhibit
efficaci
mice
accord
result
vaccin
hors
multipoint
inject
aluminium
phosphat
adjuv
employ
electropor
vaccin
mice
without
adjuv
henc
specul
electropor
necessari
mean
use
dna
immun
stimul
antibodi
respons
hors
conclus
also
confirm
report
grunwald
ulbert
saad
petrovski
worth
mention
affin
chromatographi
method
employ
studi
substanti
enrich
neutral
activ
hors
antibodi
specif
neutral
activ
igg
ic
almost
fold
higher
total
igg
ic
henc
deem
import
target
nab
hors
antisera
despit
immunogen
employ
studi
possess
fulllength
gpc
peptid
epitop
map
found
strongli
bound
igg
import
site
antibodi
bind
even
though
show
signific
bind
potenti
highli
reactiv
epitop
present
peptid
map
scheme
find
prove
receptor
recognit
subunit
pivot
target
fig
key
site
bound
antibodi
bind
igg
sixteen
peptid
deriv
junv
detect
peptid
elisa
use
posit
control
residu
igg
group
pb
group
use
control
exclud
nonspecif
bind
b
footprint
junv
colour
magenta
green
respect
shown
stick
mark
red
structur
data
process
pymol
c
bind
igg
wildtyp
wt
mutat
ala
ala
site
detect
describ
bind
igg
wt
mutat
ala
ala
site
detect
recombin
elisa
p
p
vs
control
wt
ns
signific
nab
junv
despit
antibodi
target
interfac
may
also
exist
hors
antisera
prepar
studi
actual
antibodi
target
interfac
block
structur
rearrang
requir
fusion
demonstr
effect
neutral
lassa
viru
yu
et
al
thu
antibodi
hors
antisera
target
epitop
worth
studi
summari
herein
success
obtain
potenti
nab
junv
vaccin
hors
pseudoviru
strategi
produc
purifi
neutral
igg
f
ab
could
exampl
develop
hors
immun
product
pathogen
pathogen
arenavirus
antibodi
produc
herein
highlight
potenti
therapeut
ahf
